The accumulated knowledge of how GLP‐1 receptor signalling is linked to actions in vivo, combined with growing experience of biased GLP‐1 agonists in preclinical disease models and humans, provides some clues as to whether biased agonism is a viable strategy to improve GLP‐1 receptor targeting in type 2 diabetes and other metabolic diseases. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.